Skip to main content
. Author manuscript; available in PMC: 2013 May 9.
Published in final edited form as: Br J Haematol. 2008 Mar 26;141(4):433–444. doi: 10.1111/j.1365-2141.2008.06982.x

Fig 4.

Fig 4

Overall survival post-transplant of patients treated with total therapy 2 (TT2) and total therapy 1 (TT1). (A) For patients treated on the control arm of TT2, overall survival from post-transplant consolidation was similar among patients without cytogenetic abnormalities (CA), whether receiving chemotherapy (CT) or dexamethasone (DEX), whereas there was a benefit in favour of CT versus DEX among patients with CA. NR, not reached. (B) For patients treated on the thalidomide arm of TT2, overall survival from post-transplant consolidation was similar among patients without CA and with CA, whether receiving CT or DEX. NR, not reached. (C) Among patients without CA, post-transplant survival was similar between the two arms of TT2, both of which were superior to TT1. NR, not reached. (D) Among patients with CA, post-transplant survival was similar between the control arm of TT2 and TT1, whereas those treated on the experimental arm of TT2 + THAL fared better than the two other cohorts. NR, not reached.